Physician profile
Brian M Lamb
NPI 1548365836
$2,180.40
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,462 · 2020: $314 · 2021: $15.00 · 2022: $44.83 · 2023: $230 · 2024: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $496.44 | 2019-2023 | Wegovy |
| Glaxosmithkline, LLC. | $406.10 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $310.56 | 2019-2024 | Repatha |
| Gilead Sciences, INC. | $286.04 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $118.98 | 2019-2020 | |
| Pfizer INC. | $75.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $68.10 | 2019 | |
| Sanofi-Aventis U.S. LLC | $60.86 | 2019 | |
| Abbvie INC. | $59.83 | 2021-2022 | |
| Lilly USA, LLC | $47.62 | 2019 | |
| Daiichi Sankyo INC. | $45.62 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.68 | 2019 | |
| Merck Sharp & Dohme LLC | $40.06 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.86 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.16 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.78 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $14.34 | 2019 | |
| Amarin Pharma, INC. | $11.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.